What Is Radioimmunotherapy?

The Zevalin therapeutic regimen is a type of radioimmunotherapy (RIT). You may hear your doctor, nurse, or other health care provider use the term RIT while speaking with you about the Zevalin therapeutic regimen, so it is important to understand what RIT is and how it works.

RIT is a type of anticancer treatment that combines a source of radiation, called a radioisotope, with an antibody in order to destroy cancer cells.

Radiation is a form of anticancer therapy that causes cancer cells to die. Lymphoma cells are sensitive to radiation.

Antibodies are part of the immune system, the body’s natural defense against invading organisms and foreign substances.

Antibodies travel in the bloodstream and bind to these invading organisms or foreign substances, causing other parts of the immune system to destroy and remove them from the body.

Scientists can now make antibodies, called monoclonal antibodies, that target very specific substances.3 By combining a radioisotope with a monoclonal antibody, RIT is able to deliver a dose of radiation directly to the targeted cells

What Is Zevalin?

Zevalin® (ibritumomab tiuxetan) is a form of radioimmunotherapy (a radiolabeled monoclonal antibody) indicated for treatment of patients with relapsed or refractory, low grade or follicular B-cell non-Hodgkin's lymphoma (NHL) or for patients with previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy. "Refractory" refers to a disease that is no longer responding, or never responded, to common treatments.

Zevalin is the first radioimmunotherapy treatment to be FDA-approved as part of first-line therapy for follicular NHL. Radioimmunotherapy (RIT) is an innovative form of cancer treatment with a mechanism of action that is different from traditional chemotherapy. RIT builds on the combined effect of a targeted biologic monoclonal antibody augmented with the therapeutic effects of a beta-emitting radioisotope.

How It Works

Rituxan and Zevalin both target B-cells by binding to the CD20 antigen which is found on the surface of all B-cells. Zevalin is especially effective because radiation from the Y-90 isotope contained in the second Zevalin treatment, enhances the destruction of not only B-cells but of surrounding cells which may also be malignant.

It is true that, because the antibody attaches to all B-cells, that the therapy kills both healthy and unhealthy cells. Precursor cells, however, are not targeted; they remain to replenish the blood with non-cancerous B-cells.

Zevalin treatment has been shown to be extremely effective and has the added benefit of being a fast therapy that is carried out in 7-9 days. However, because it employs radioactive isotopes, Zevalin can only be administered by qualified physicians at nuclear medicine facilities.

Side Effects

The Zevalin therapeutic regimen can cause serious side effects including:

  • Serious Infusion Reactions: Rituximab, alone or as part of the Zevalin therapeutic regimen, may cause serious infusion reactions. Tell your doctor or infusion nurse or get medical treatment right away if you develop fever or chills, a rash, itching, dizziness, swelling of your hands, feet or face, throat irritation or trouble breathing during or after administration of the Zevalin therapeutic regimen.
  • Prolonged and severe decreases in your blood counts: Your doctor will monitor your blood counts after receiving the Zevalin therapeutic regimen. Tell your doctor if you have a fever, feel too tired to do daily activities, feel weak, develop bruises, have unusual bleeding or notice blood in your urine or stool.
  • Severe skin reactions: Tell your doctor, infusion nurse or get medical treatment right away if you develop sores on your skin or in your mouth or if your skin is peeling or blistering during or after receiving the Zevalin therapeutic regimen.

Other potential serious and life-threatening side effects include:

  • Extravasation: Extravasation happens when some of the drug in an IV infusion or injection, or the vein it is being injected into, leaks into the surrounding tissue. Immediately tell your doctor or infusion nurse if you have burning, pain, stinging, redness or swelling around the site in your arm where your medication is being given by vein.
  • Leukemia and Myelodysplastic Syndrome: Sometimes following treatment for NHL, patients develop leukemia or myelodysplastic syndrome. This has been reported in patients that have received the Zevalin therapeutic regimen. Be sure to discuss this potential serious and life-threatening side effect with your doctor.
  • Infections: The Zevalin therapeutic regimen may increase your chance of getting an infection. Be sure to tell your doctor immediately if you develop a fever, have a cough or have any flu-like symptoms.

The most common side effects of Zevalin are:

  • Decreased blood counts
  • Fatigue
  • Stomach pain
  • Nausea
  • Weakness
  • Diarrhea
  • Cough
  • Fever
  • Nose and upper throat irritation

Because the Zevalin therapeutic regimen includes the use of rituximab, see prescribing information for rituximab.

For more information on Non-Hodgkin Lymphoma and radioimmunotherapy, please see the following pages:

 Related Articles

The ZEVALIN therapeutic regimen decreased the
risk of disease progression by 54% when used after patients with specific kinds of NHL responded to first-line chemotherapy.

The Zevalin Treatment Schedule

The Zevalin therapeutic regimen consists of rituximab and Yttrium-90 radiolabeled Zevalin (Y-90). The Zevalin therapeutic regimen is given on the following schedule:

Day One
Day 1
Premedication with acetaminophen and diphenhydramine followed by administration of rituximab.
Day Seven, Eight or Nine
Premedication with acetaminophen and diphenhydramine followed by administration of a rituximab infusion. Within 4 hours of the rituximab infusion, Y-90 Zevalin is given as an intravenous injection. Y-90 Zevalin is a monoclonal antibody combined with a radioisotope that attacks B-cells and is the therapeutic component of the Zevalin therapeutic regimen.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...